Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dovitinib + XELOX in advanced colorectal and gastric cancer
NCT02720926Phase 1Terminated
- Sponsor
- National Cancer Centre Singapore
- Start
- Sep 2011
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dovitinib in colorectal cancer (CRC) and gastric cancer (GC), sponsored by National Cancer Centre Singapore. Primary endpoint: Recommended Phase 2 Dose at 42 days. Started Sep 2011; status: terminated.
02
Drugs
dovitinib
03
Conditions
colorectal cancer (CRC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT02720926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02720926.